Olivia Blair
Mt Pleasant, SCNPI 1982274775
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Amgen at 30.8% of the total.
Across 140 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$817
- IBSA Pharma Inc.$499
- Amneal Pharmaceuticals LLC$311
- Novo Nordisk$306
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$236
- Lilly USA, LLC$184
- plus $303 from 10 others
What the payments were for
- Food & beverage$2,655100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 49 | $817 |
| IBSA Pharma Inc. | 25 | $499 |
| Amneal Pharmaceuticals LLC | 19 | $311 |
| Novo Nordisk | 15 | $306 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $236 |
| Lilly USA, LLC | 9 | $184 |
| AbbVie | 4 | $76 |
| Eisai Inc. | 2 | $47 |
| Madrigal Pharmaceuticals | 2 | $46 |
| AstraZeneca | 1 | $25 |
| Virtus Pharmaceuticals LLC | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Bayer | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 67 | $6,511 |
| Liothyronine Sodium | 69 | $5,025 |
| Levothyroxine Sodium | 85 | $880 |
| Metformin Hcl ErMetformin Hcl | 13 | $443 |
| ProgesteroneProgesterone, Micronized | 18 | $243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $76 | $6,51167 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $311 | $88085 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.